Details of Disease

Disease Name

Drug-resistant tuberculosis

drug resistant tuberculosis

Definition

Tuberculosis disease caused by Mycobacterium tuberculosis isolate that is resistant to one or more of the antitubercular medications.

Disease Hierarchy

DIS2YIMD: Tuberculosis

DIS5BUFB: Drug-resistant tuberculosis

Disease Identifiers

MONDO ID

MONDO_0041806

MESH ID

D018088

UMLS CUI

C0206525

MedGen ID

61616

SNOMED CT ID

423709000

General Information of Disease (ID: DIS5BUFB)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bedaquiline	DM3906J	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
KCNA5	TTW0CMT	Strong	Genetic Variation	[2]
KCNK3	TTGR91N	Strong	Genetic Variation	[2]
PRG4	TTSKF4V	Strong	Genetic Variation	[3]
RNF34	TTEWDK1	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FASTK	OTTHFZMP	Limited	Biomarker	[5]
INHA	OT7HWCO3	Strong	Genetic Variation	[6]
KCNA4	OTTIGYN7	Strong	Genetic Variation	[2]
RHOF	OTPA3F8Q	Strong	Biomarker	[4]
SIT1	OT7MDF09	Strong	Biomarker	[7]
SRL	OT7IEBWZ	Strong	Biomarker	[8]
NCAPG2	OTZYENKO	Definitive	Biomarker	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DOT(s)

References

1	Bedaquiline FDA Label
2	3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel.Bioorg Med Chem. 2019 Apr 1;27(7):1292-1307. doi: 10.1016/j.bmc.2019.02.026. Epub 2019 Feb 15.
3	Beyond 'cure' and 'treatment success': quality of life of patients with multidrug-resistant tuberculosis.Int J Tuberc Lung Dis. 2019 Jan 1;23(1):73-81. doi: 10.5588/ijtld.18.0149.
4	Abbott RealTime MTB and MTB RIF/INH assays for the diagnosis of tuberculosis and rifampicin/isoniazid resistance.Infect Genet Evol. 2019 Jul;71:54-59. doi: 10.1016/j.meegid.2019.03.012. Epub 2019 Mar 20.
5	Turning Off the Tap: Using the FAST Approach to Stop the Spread of Drug-Resistant Tuberculosis in the Russian Federation.J Infect Dis. 2018 Jul 13;218(4):654-658. doi: 10.1093/infdis/jiy190.
6	High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.PLoS One. 2015 Sep 2;10(9):e0135003. doi: 10.1371/journal.pone.0135003. eCollection 2015.
7	Genotypic diversity of multidrug-, quinolone- and extensively drug-resistant Mycobacterium tuberculosis isolates in Thailand.Infect Genet Evol. 2015 Jun;32:432-9. doi: 10.1016/j.meegid.2015.03.038. Epub 2015 Apr 4.
8	Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.Eur J Med Chem. 2017 Feb 15;127:147-158. doi: 10.1016/j.ejmech.2016.12.042. Epub 2016 Dec 23.